Book chapter · 2023
Is progression-free survival a rational surrogate endpoint in front-line ovarian cancer clinical trials?
Cambridge University Press eBooks, 161–164 · Published 19 July 2023 · DOI 10.1017/9781108935579.054
In brief
“Is progression-free survival a rational surrogate endpoint in front-line ovarian cancer clinical trials?” is a 2023 book chapter by Éric Pujade-Lauraine and 2 co-authors, published in Cambridge University Press eBooks. OpenAlex counts 0 citations as of 22 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 0
- References
- 7
- Authors
- 3
Abstract
Selection of clinical trial endpoints is a critical decision for investigators. Choosing a poor endpoint can result in false discovery or thwart regulatory approval. Overall survival (OS) is the most objective clinical trial endpoint; however, use of this endpoint is impractical in some tumors. A prime example is in epithelial ovarian cancer where the case… Read the full abstract at the publisher.
Excerpt. This paper is not open access.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Pujade-Lauraine, É., You, B., & Frenel, J. (2023). Is progression-free survival a rational surrogate endpoint in front-line ovarian cancer clinical trials? Cambridge University Press eBooks, 161–164. https://doi.org/10.1017/9781108935579.054
MLA 9
Pujade-Lauraine, Éric, et al. “Is progression-free survival a rational surrogate endpoint in front-line ovarian cancer clinical trials?” Cambridge University Press eBooks, 2023, pp. 161–164. https://doi.org/10.1017/9781108935579.054.
Chicago
Pujade-Lauraine, Éric, Benoît You, and Jean‐Sébastien Frenel. 2023. “Is progression-free survival a rational surrogate endpoint in front-line ovarian cancer clinical trials?” Cambridge University Press eBooks: 161–164. https://doi.org/10.1017/9781108935579.054.
Harvard
Pujade-Lauraine, É., You, B. and Frenel, J. (2023) ‘Is progression-free survival a rational surrogate endpoint in front-line ovarian cancer clinical trials?’, Cambridge University Press eBooks, pp. 161–164. doi:10.1017/9781108935579.054.
IEEE
É. Pujade-Lauraine, B. You, and J. Frenel, “Is progression-free survival a rational surrogate endpoint in front-line ovarian cancer clinical trials?,” Cambridge University Press eBooks, pp. 161–164, 2023, doi: 10.1017/9781108935579.054.
BibTeX
@incollection{pujadelauraine2023progression,
title = {{Is progression-free survival a rational surrogate endpoint in front-line ovarian cancer clinical trials?}},
author = {Pujade-Lauraine, Éric and You, Benoît and Frenel, Jean‐Sébastien},
booktitle = {Cambridge University Press eBooks},
publisher = {Cambridge University Press},
year = {2023},
pages = {161--164},
doi = {10.1017/9781108935579.054},
url = {https://doi.org/10.1017/9781108935579.054}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- progression-free survival
- surrogate endpoints
- ovarian cancer
- first-line therapy
- overall survival
- clinical trial endpoints
- post-progression survival
- regulatory approval
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Pujade-Lauraine, É., You, B., & Frenel, J. (2023). Is progression-free survival a rational surrogate endpoint in front-line ovarian cancer clinical trials? Cambridge University Press eBooks, 161–164. https://doi.org/10.1017/9781108935579.054
How many times has this paper been cited?
0 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Éric Pujade-Lauraine, Benoît You, Jean‐Sébastien Frenel.
What is the DOI of this paper?
10.1017/9781108935579.054, permanently at https://doi.org/10.1017/9781108935579.054. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.